Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen

Antiviral Therapy

Volumn 19, Issue 4, 2014, Pages 399-406

  Moholisa, Retsilisitsoe R ^a   Schomaker, Michael ^a   Kuhn, Louise ^b   Meredith, Sandra ^a   Wiesner, Lubbe ^a   Coovadia, Ashraf ^c   Strehlau, Renate ^c   Martens, Leigh ^c   Abrams, Elaine J ^d   Maartens, Gary ^a   McIlleron, Helen ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d Empilweni Services and Research Unit Rahima Moosa Mother and Child Hospital University of Witwatersrand ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

AGE DISTRIBUTION; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CHILD; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SOUTH AFRICAN; TREATMENT DURATION; VIRUS LOAD; DRUG MONITORING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; PRESCHOOL CHILD; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; VIREMIA; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 84929506097     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2749     Document Type: Article

References (23)

1. Penazzato M, Prendergast A, Tierney J, Cotton M, Gibb D. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age. Cochrane Database Syst Rev 2012; 7:CD004772.
2. Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS 2012; 26:929-938.
3. Bain-Brickley D, Butler LM, Kennedy GE, Rutherford GW. Interventions to improve adherence to antiretroviral therapy in children with HIV infection. Cochrane Database Syst Rev 2011; 12:CD009513.
4. Resino S, Bellón JM, Ramos JT, et al. Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2004; 23:923-930.
5. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010; 363:1510-1520.
6. World Health Organization. Antiretroviral therapy of HIV infection in infants and children: towards universal access: recommendations for a public health approach - 2010 revision. Geneva: World Health Organization, 2010.
7. Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med 2004; 5 Suppl 2:61-86.
8. Rudin C, Wolbers M, Nadal D, Rickenbach M, Bucher HC. Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children. Arch Dis Child 2010; 95:478-481.
9. Taylor BS, Hunt G, Abrams EJ, et al. Rapid Development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses 2011; 27:945-956.
10. van Zyl GU, van Mens TE, McIlleron H, et al. Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr 2011; 56:333-339.
11. Coovadia A, Abrams EJ, Stehlau R, et al. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA 2010; 304:1082-1090.
12. Kuhn L, Coovadia A, Strehlau R, et al. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis 2012; 12:521-530.
13. Reitz C, Coovadia A, Ko S, et al . Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. J Infect Dis 2010; 201: 1121-1131.
14. Child growth standards: WHO Anthro (version 3.2.2, January 2011) and macros. Geneva: World Health Organization. (Updated January 2011. Accessed 11 August 2010.) Available from http://www.who.int/childgrowth/software/en/
15. Honaker J, King G. What to do about missing values in time-series cross-section data. Am J Pol Sci 2010; 54:561-581.
16. + years. J Am Stat Assoc 1996; 91:473-489.
17. Hens N, Aerts M, Molenberghs G. Model selection for incomplete and design-based samples. Stat Med 2006; 25:2502-2520.
18. R Development Core Team. R: a language and environment for statistical computing. Version 2.15.3. Vienna: R Foundation for Statistical Computing 2010.
19. Kabue MM, Kekitiinwa A, Maganda A, Risser JM, Chan W, Kline MW. Growth in HIV-infected children receiving antiretroviral therapy at a pediatric infectious diseases clinic in Uganda. AIDS Patient Care STDS 2008; 22:245-251.
20. Treluyer JM, Burgard M, Cazali N, et al. Relationship between antiretroviral drug plasma concentrations and viral load in children. J Acquir Immune Defic Syndr 2003; 32:112-115.
21. La Porte CJL, Back DJ, Blaschke T, et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther 2006; 3:4-14.
22. Chadwick EG, Pinto J, Yogev R, et al. Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy. Pediatr Infect Dis J 2009; 28:215-219.
23. Ren Y, Nuttall JJC, Egbers C, et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2008; 47: 566-569.